MorphoSys CEO Simon Moroney leaves

  • Push-out Score determined
  • After 25 years in the position
  • Accolades and praise for Moroney
  • Search for a successor
  • Moroney said 102 words

(exechange) — Planegg/Munich, Germany, February 19, 2019 — Simon Moroney, chief executive of MorphoSys, leaves. As announced by MorphoSys AG in a news release on Tuesday, February 19, 2019, Simon E. Moroney leaves his post as Chief Executive Officer at the clinical-stage biopharmaceutical company after 25 years in the role.

It is the end of an era.

“As a result of his decision, Dr. Moroney will step down as CEO on expiry of his current contract on June 30, 2020, or when a successor is appointed, whichever comes sooner,” MorphoSys said.

MorphoSys will undertake a search for a successor.

“I am looking forward to having more time for other interests, and to exploring new opportunities”

Simon Moroney’s departure from the CEO post is explained as follows. Moroney said: “After dedicating such a long time to MorphoSys, I am looking forward to having more time for other interests, and to exploring new opportunities.”

The phrase “I am looking forward to having more time for other interests, and to exploring new opportunities” opens the door to speculation.

Precise information regarding Simon Moroney’s future plans was not immediately available.

“He has decided not to renew his contract”

MorphoSys said: “Simon Moroney, CEO and co-founder of MorphoSys AG …, informed the Company’s Supervisory Board today that he has decided not to renew his contract as a member of the company’s Management Board.”

In the position of CEO since 1994

Moroney co-founded MorphoSys in 1992, becoming Chief Executive Officer in 1994, a position that he has filled until the present time.

Under his leadership, MorphoSys has grown to become one of the biopharmaceutical industry’s most important companies, with one of the broadest pipelines of drug candidates.

Prior to founding MorphoSys, Moroney held academic positions at the University of Cambridge, England, the University of British Columbia, Canada, the ETH Zürich, Switzerland and Harvard Medical School.

While at Harvard Medical School he worked for ImmunoGen Inc.

He received his D. Phil in chemistry as a Commonwealth Scholar at the University of Oxford in 1984 and an M.Sc with 1st class honours in chemistry from the University of Waikato in his native New Zealand in 1981.

Awards include the State Medal for Outstanding Services to the Bavarian Economy (2009), World Class New Zealand Award for Biotechnology (2006) and the German Cross of the Order of Merit (Bundesverdienstkreuz am Bande) (2004).


Generally speaking, when a top leader announces to step aside with no successor available, it is a sign that the change was unexpected and too early.

Push-out Score determined

The Push-out Score™ determined by exechange gauges the likelihood that a manager was pushed out or felt pressure to leave the position.

exechange reached out to MorphoSys and offered the company the opportunity to comment on the score.

Read the full story in the exechange report 8.2019 ($).